ForPatients
by Roche

Breast Cancer

A study to compare the study medicine (GDC-0810) to another treatment (fulvestrant) in patients with breast cancer

A Study of GDC-0810 Versus Fulvestrant in Postmenopausal Women With Advanced or Metastatic Breast Cancer Resistant to Aromatase Inhibitor (AI) Therapy

Trial Status	Trial Runs In	Trial Identifier
Terminated	6 Countries	NCT02569801 2015-000106-19 GO29689

The source of the below information is the publicly available website ClinicalTrials.gov. It has been summarised and edited into simpler language.

Trial Summary:

The primary purpose of this study is to evaluate the efficacy, safety, and tolerability of GDC-0810 compared with fulvestrant in postmenopausal women with advanced or metastatic estrogen receptor positive (ER+)/ human epidermal growth factor receptor 2 negative (HER2-) breast cancer resistant to AI therapy. The development of GDC-0810 has been halted by the Sponsor and the enrollment in this study has been discontinued. Participants currently enrolled in the study who are experiencing clinical benefit may continue receiving GDC-0810 as a single agent or fulvestrant until disease progression (PD), unmanageable toxicity, withdrawal of consent, exhaustion of GDC-0810 drug supply, or termination of the study by the Sponsor.

Genentech, Inc. Sponsor	**Phase 2** Phase

NCT02569801 2015-000106-19 GO29689
Trial Identifiers

Eligibility Criteria:

Gender	Age	Healthy Volunteers
Female	>=18 Years	No

This clinical trial was done to study a new medicine called, “GDC-0810”. Researchers wanted to find out how effective GDC-0810 was for patients with ER+/HER2- breast cancer, in comparison to an approved treatment (fulvestrant). Seventy-one patients took part in this study at 26 study centers in 6 countries.